HER2-positive Patients Receiving Trastuzumab Treatment Have a Comparable Prognosis with HER2-negative Advanced Gastric Cancer Patients: a Prospective Cohort Observation.

Miao-Zhen Qiu,Qian Li,Zhi-Qiang Wang,Tian-Shu Liu,Qing Liu,Xiao-Li Wei,Ying Jin,De-Shen Wang,Chao Ren,Long Bai,Dong-Sheng Zhang,Feng-Hua Wang,Yu-Hong Li,Rui-Hua Xu
DOI: https://doi.org/10.1002/ijc.28559
2013-01-01
International Journal of Cancer
Abstract:The monoclonal antibody trastuzumab has brought survival benefit to patients with advanced gastric cancer (AGC) that have human epidermal growth factor receptor 2 (HER2) over expression or amplification. This study was designed to compare the clinical outcomes of HER2‐negative and HER2‐positive AGC patients with or without trastuzumab treatment. There were three groups of patients enrolled for analysis. Group A was 51 HER2‐positive AGC patients treated with trastuzumab and chemotherapy; group B was a matched control group of 47 HER2‐positive patients who received chemotherapy only; group C was a matched group of 251 HER2‐negative patients who received chemotherapy. All the patients were enrolled at Sun Yat‐sen University Cancer Center or Zhongshan Hospital, Fudan University between January 2010 and December 2012. The primary endpoint was overall survival (OS). The Kaplan‐Meier method and log‐rank test were used for survival analysis. The median duration of follow‐up was 13.5 months (range 5–18.6 months). The median OS of these three groups of patients was 14.8 months, 11.3 months and 14.4 months respectively (p < 0.001). The survival difference between group A and B was significant, p < 0.001. Similarly, there was significant difference between group B and C, p < 0.001. Moreover the survival between group A and C was comparable, p = 0.281. The median progression‐free survival for these three groups was 7.4, 6.0 and 7.2 months. Multivariate analysis confirmed that trastuzumab treatment was an independent prognostic factor in group A and B patients (p = 0.017). HER2 positive was an independent adverse prognostic factor in group B and C patients (p = 0.013).
What problem does this paper attempt to address?